TABLE 1.
The expression pattern of PEPCK‐M in breast cancer by ER, PR, HER2/neu status, and intrinsic subtype
| Expression of PEPCK‐M (N [%]) | p‐value a | ||||
|---|---|---|---|---|---|
| 0 | 1+ | 2+ | 3+ | ||
| Patient number (%) | 4 (2%) | 45 (25%) | 93 (53%) | 35 (20%) | |
| Estrogen receptor | |||||
| Negative | 1 (2%) | 23 (44%) | 19 (36%) | 10 (19%) | 0.004 |
| Positive | 3 (2%) | 22 (18%) | 74 (60%) | 25 (20%) | |
| Progesterone receptor | |||||
| Negative | 3 (3%) | 31 (30%) | 50 (49%) | 19 (18%) | 0.303 |
| Positive | 1 (1%) | 14 (19%) | 43 (58%) | 16 (22%) | |
| HER2/neu | |||||
| Negative | 3 (3%) | 34 (28%) | 60 (49%) | 24 (20%) | 0.647 |
| Positive | 1 (2%) | 11 (20%) | 32 (59%) | 10 (19%) | |
| Intrinsic subtype | |||||
| Luminal A | 1 (2%) | 10 (23%) | 21 (49%) | 11 (26%) | 0.049 |
| Luminal B1 | 2 (4%) | 10 (19%) | 32 (59%) | 10 (19%) | |
| Luminal B2 | 0 | 3 (10%) | 21 (70%) | 6 (20%) | |
| HER2/neu‐enriched | 1 (4%) | 8 (33%) | 11 (46%) | 4 (17%) | |
| Basal‐like | 0 | 14 (54%) | 8 (31%) | 4 (15%) | |
a
Chi‐square test.